Novo Nordisk
Novo Nordisk is a global healthcare company focused on the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of diabetes, obesity and haemophilia. Within the company’s diabetes and obesity segment it concentrates on insulin, GLP-1 and other protein-related products as well as delivery systems and needles and oral anti-diabetic drugs. Within the biopharmaceuticals segment, it covers haemophilia care, growth hormone therapy and hormone replacement therapy.
Visit their site- Enterprise value
- US$384.4 bn
- Region
- Denmark
- Theme
- Health
- Sub-theme
- Pharmaceutical therapies
Impact Score
Many of Novo Nordisk’s therapies are given to patients who would either die or experience a dramatically lower quality of life without them. While the drugs are providing benefits to a vulnerable population, it also tends to be one that is well-served.
Fundamental Quality
Novo is an impressive company driven by R&D and purpose, with a strong track record of innovation. ESG considerations are integrated within the company’s pursuit of doing business the “Novo Nordisk Way”, which is the basis for its guiding principles used in decision making.
UN SDGs
Novo Nordisk’s products are critical to the survival or quality of life of those with debilitating diseases, thus supporting SDG3.
Find out moreRisk of negative impacts
- Side-effects from pharmaceuticals
- Product pricing restricts access for poor communities
- Plastic waste from packaging
- Animal testing of pharmaceuticals
Related insights Related
Sustainable
The next constraint on AI is not just energy, it's also water
By Ty Lee
10 Mar 2026 | 3 min read
Sustainable
From villain to saviour – renewable energy is coming to the rescue
By WHEB Investment Team
17 Feb 2026 | 6 min read
Sustainable
Are EVs really rolling backwards?
By WHEB Investment Team
19 Jan 2026 | 5 min read
Sustainable
Sustainable investment trends for 2026
By Seb Beloe
19 Jan 2026 | 5 min read